Legal Trouble for uniQure Over AMT-130 Misleading Claims in Class Action Lawsuit

uniQure Faces Class Action Lawsuit Over AMT-130 Claims

uniQure N.V. is presently embroiled in legal challenges as a class action lawsuit is filed against the company, alleging violations of the Securities Exchange Act of 1934. The lawsuit, brought forth by the DJS Law Group, pertains to misleading statements made concerning the development and regulatory prospects of its gene therapy AMT-130 for Huntington’s disease. Investors who purchased shares during the class period from September 24, 2025, to October 31, 2025, are encouraged to seek participation, especially as the suit contends that uniQure downplayed significant delays related to its Biologics License Application (BLA) and the adequacy of its pivotal study design.

The crux of the allegations is that uniQure’s communications regarding its Phase 1/2 clinical trial misrepresented the interplay between this study and the ENROLL-HD dataset. Investors claim that the company’s disclosures failed to encapsulate potential obstacles to FDA approval, thereby creating a misleading narrative about AMT-130’s development trajectory. As the lawsuit unfolds, the DJS Law Group aims to advocate on behalf of affected investors, seeking a remedy for potentially significant financial losses incurred during the specified timeline.

The implications of this lawsuit extend beyond investor recourse, reflecting the high-stakes nature of the biotechnology industry where the success of therapies can hinge on regulatory approvals. uniQure’s management now grapples with the complex regulatory landscape, especially in light of recent FDA guidance cautioning against relying solely on early data from the clinical study for marketing applications. This legal pressure comes at a time when uniQure strives to solidify its market position with innovative treatments amid evolving industry challenges.

In conjunction with the lawsuit developments, uniQure recently reported a 25% increase in Q4 revenue year-over-year, driven mainly by the commercialization of its gene therapy products. However, the company is concurrently dealing with the scrutiny surrounding AMT-130, which underscores the dual pressures of maintaining fiscal growth while navigating significant legal and regulatory hurdles.

As the deadline for investors to join the class action lawsuit approaches on April 13, 2026, stakeholders will closely monitor how these developments affect uniQure's strategy and operations. The ongoing situation illustrates the tensions that can arise in the drug development process, particularly when investor expectations clash with regulatory realities.